Afghanistan's decision to overhaul its medicine market was meant to improve quality and boost domestic production, but industry specialists say the swift changes have led to a litany of problems.

President and CEO Liz Barrett outlined the company’s urothelial cancer focus and provided an update on the commercial launch ...